常规应用东菱迪芙防治血管常见疾病的疗效观察.pdfVIP

中国医疗前沿 2007 年4 月第2 卷第8 期 China Healthcare innovation , April 2007 ， γ。1. 2 ,No. 8 19 常规应用东菱迪芙防治血管常见疾病的疗效观察 原标，宋盛晗，李谈，张望德，苑超 (首都医科大学附属北京朝阳医院血管外科，北京 10020) 【摘要】目的观察常规应用东菱边笑防治血管常见疾病的疗效及安全性。方法于 2002 年 3 月 -2007 年 3 月对血管 外科常见疾病 309 例常规应用东菱边芙(巳曲酶注射液)予以降纤治疗，住院期间所有患者血浆纤维蛋白原均控制在 60- 120mgldl 目标范围，记录患者对东菱边芙产生的药物不良反应，以及用药前后血常规、凝血四项及血生化全项的变化。结果 住院期间所有患者在用药过程中未发现明显的药物不良反应，没有观察到任何出血征兆;用药前后比较，血常规、凝血四项 及生化全项各指标均未观察到有统计学意义的变化。结论东菱边芙具有显著的降纤效果且使用安全可靠，建议针对临床 合并高纤维蛋白原血症的患者可以常规应用东菱边芙行降纤治疗，从而有利于患者康复。 【夫键词】东菱边芙;纤维蛋白原;降纤治疗;常规应用;血管常见疾病 【中图分类号】 R54 【文献标识码1 A 【文章编号1 1673-5552[2007]04-19-03 Preventive and Treatment Eflicacy of Batroxobin on Vascular Occlusive Diseases YUAN Biao ,SONG Shen-han,Ll Tan,ZHANG Wang-de ,YUAN Chao (Department of vascular surgery,Beijing Chao-Yang Hospital, A组liate of Capital University of Medical Sciences, 10020) [ABSTRACT] Objective To observe the efficacy and safety of Batroxobin injection which was administered in the prevention and treatment of vascular occlusive diseases.Methods Batroxobin injection was routinely administered to 309 cases vascular occlusive diseases. 60 -12Omg/dl is the target value of fibrinogen level during hospital period. Laboratory tests were required ,such as determination of the blood fibrinogen concentration and tbe aggregation of platelets during 也e course of administration of the medicine.Results All those patients had not ob悦。us adverse reactions ,especially hemorrhagic tendency. ηlere were not significant statiscal difference in blood ,liver and kidney function.Conclusion Batroxobin injection which is a safe and effective defibrinogenation therapy should be routinely administered in the prevention and treatment of hyperfibrinogenemia of vascular occlusive diseases . [KEY WORDS] Batroxobin injection;Fibrinogen level;